11140

Satellite Symposia: Debating Key Concepts in the Management of Nonalcoholic Steatohepatitis

Date
May 7, 2023

Society: DDW

Medscape Prorgam Description Pending Supporter Supported by an independent educational grant from Madrigal Pharmaceuticals. CME For Physicians Medscape, LLC designates this live activity for a maximum of 1.0 AMA PRA Category 1 Creditsª. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Tracks

Related Products

Thumbnail for INVESTIGATING THE EFFICACY OF ALPELISIB AND PI3Kα-S6K DUAL INHIBITION IN LIN28B-DRIVEN COLORECTAL CANCER METASTASIS
INVESTIGATING THE EFFICACY OF ALPELISIB AND PI3Kα-S6K DUAL INHIBITION IN LIN28B-DRIVEN COLORECTAL CANCER METASTASIS
Colorectal cancer (CRC) shows a dramatic drop in the five-year survival rate from 90% for localized tumors to 14% for metastatic CRC (mCRC). Our lab has identified LIN28B, an RNA-binding protein overexpressed in 30% of CRCs, as an oncogene that promotes CRC metastasis…
Thumbnail for STUDYING THE THERAPEUTIC BENEFITS OF INNATE IMMUNE STIMULI IN HEPATOCELLULAR CARCINOMA
STUDYING THE THERAPEUTIC BENEFITS OF INNATE IMMUNE STIMULI IN HEPATOCELLULAR CARCINOMA
Beyond personal hygiene, the most impactful public health innovation in human history has been the development of vaccines, which has allowed many scourges of humanity, such as smallpox, to been eradicated or reduced to clinical inconsequentiality…
Thumbnail for SURVODUTIDE REDUCES LIVER FAT CONTENT, TRANSAMINASES, AND FIBROSIS MARKERS WITH GOOD SAFETY PROFILE IN PEOPLE WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH): AN INTERIM ANALYSIS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 TRIAL
SURVODUTIDE REDUCES LIVER FAT CONTENT, TRANSAMINASES, AND FIBROSIS MARKERS WITH GOOD SAFETY PROFILE IN PEOPLE WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH): AN INTERIM ANALYSIS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 TRIAL
BACKGROUND: Survodutide is a novel glucagon receptor/glucagon-like peptide-1 receptor dual agonist under investigation for treatment in advanced liver disease associated with metabolic dysfunction-associated steatohepatitis (MASH), the most severe form of metabolic dysfunction-associated steatotic…
Thumbnail for COMPARATIVE ANALYSIS OF GENE EXPRESSION PROFILES OF ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMAS BASED ON ANATOMICAL CLASSIFICATION
COMPARATIVE ANALYSIS OF GENE EXPRESSION PROFILES OF ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMAS BASED ON ANATOMICAL CLASSIFICATION
BACKGROUND: Siewert's topographic classification (SW) has been used for treatment plan of esophagogastric junction adenocarcinomas (EGJA). But recently, molecular classifications categorized EGJA with similar characteristics and prognosis…